A metabolite of choline, phosphatidylcholine, and L-carnitine
Related Products
Technical Support & Resources

Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

Trimethylamine N-oxide (hydrate)

Item No. 17354

Technical Information
Formal Name
N,N-dimethyl-methanamine, N-oxide, hydrate
Synonyms
  • TMAO
Molecular Formula
C3H9NO • XH2O
Formula Weight
Purity
≥95%
A crystalline solid
DMF: 1 mg/mlDMSO: 1 mg/mlEthanol: 25 mg/mlPBS (pH 7.2): 10 mg/ml
SMILES
C[N+]([O-])(C)C.O
InChi Code
InChI=1S/C3H9NO.H2O/c1-4(2,3)5;/h1-3H3;1H2
InChi Key
GYFWCKUYWWTXCE-UHFFFAOYSA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

    Add

    Add

    Add

    Product Description

    Trimethylamine N-oxide (TMAO) is a metabolite of choline, phosphatidylcholine, and L-carnitine (Item No. 21489).1 It is formed by gut microbiota-mediated metabolism of choline, phosphatidylcholine, and L-carnitine to TMA followed by oxidation of TMA by flavin-containing monooxygenase 3 (FMO3) in the liver.1,2,3 Dietary administration of TMAO (0.12% w/w) increases renal tubulointerstitial fibrosis, collagen deposition, and Smad3 phosphorylation in mice and increases aortic lesion area in atherosclerosis-prone ApoE-/- mice.1,4 Plasma levels of TMAO are elevated in patients with chronic kidney disease and decreased in patients with active, compared with inactive, ulcerative colitis.1,2 Elevated plasma levels of TMAO are associated with increased risk of cardiovascular disease.4

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Tang, W.H.W., Wang, Z., Kennedy, D.J., et alGut microbiota-dependent trimethylamine N-oxide (TMAO) pathway contributes to both development of renal insufficiency and mortality risk in chronic kidney disease. Circ. Res. 116(3), 448-455 (2015).

    2. Wilson, A., Teft, W.A., Morse, B.L., et alTrimethylamine-N-oxide: A novel biomarker for the identification of inflammatory bowel disease. Dig. Dis. Sci. 60(12), 3620-3630 (2015).

    3. Zhang, L.S., and Davies, S.S. Microbial metabolism of dietary components to bioactive metabolites: Opportunities for new therapeutic interventions. Genome Med. 8(1), 46 (2016).

    4. Wang, Z., Klipfell, E., Bennett, B.J., et alGut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature 472(7341), 57-63 (2011).